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Abstract. Developing countries like Pakistan have previously suffered from barriers to acceptance of vaccination by
the public because of financial and belief barriers. This study aims to explore these beliefs and highlight concerns regard-
ing vaccine hesitancy in the general population of Pakistan since they are a hindrance to an effective coronavirus
disease-19 (COVID-19) immunization in the country. A cross-sectional study was performed involving 1,778 participants
from all four provinces of Pakistan. Results from the study showed more than half of the participants to be unsure of the
safety (50%) and efficacy (51%) of the vaccine, whereas 42% were concerned about the side effects of the vaccine.
About 72% of the respondents planned to get vaccinated, whereas 28% refused to do so. Internationally made imported
vaccines were more trusted by the participants. Forty-four percent of the participants agreed to receive the vaccine upon
recommendation from a physician. Lastly, participants who believed in the efficacy of the polio vaccination also consid-
ered the COVID-19 vaccine to be safe and effective.
INTRODUCTION
Coronavirus disease-2019 (COVID-19), caused by the
severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) is suspected to be have originated in the city of
Wuhan, China, and was declared as a pandemic by the
WHO on March 11, 2020.1 Since its discovery on December
12, 2019, the disease has affected the whole world killing
millions of people to this day.2 The outbreak has also caused
huge negative impacts on the public health system as well
as disrupting the perception of public health according to
many people.3,4 Currently, there is no specific cure in the
treatment of COVID-19 as the effects of different medica-
tions are still being investigated in clinical trials.5 The current
treatment is that of supportive care such as oxygenation and
fluid therapy, and preventive methods to reduce the spread
of the highly transmissible SARS-CoV-2.6
According to the Centers for Disease Control and Preven-
tion (CDC), all authorized vaccines are efficacious against
symptomatic, laboratory confirmed (65–95%) COVID-19
infections, and can prevent hospitalization from severe
COVID-19 infection ($ 89%).7 The BNT162b2 vaccine in its
phase 3 clinical trial showed an efficacy of 90.5% in prevent-
ing COVID-19, 2 to 7 days after the second dose.8 Similarly,
the mRNA-1273 had shown an efficacy of 94.1% in prevent-
ing symptomatic disease, with a median follow-up of 2
months after completion of the two-dose regimen.9 How-
ever, there results only show short-term efficacies of the
vaccines. Since there is no clinical data on the long-term effi-
cacy of the COVID-19 vaccines, it can perhaps be predicted
using the decay in neutralizing titers following vaccination.
One study found a nonlinear strong relationship between the
mean in-vitro neutralization levels, and the reported efficacy
of seven vaccines from their phase 3 clinical trials, namely
mRNA-1273, NVX-CoV2373, BNT162b2, rAd26-S1rAd5-S,
ChAdOx1 nCoV-19, Ad26.COV2. S, and CoronaVac.10
This model compared the decay in the neutralization titers
with the convalescent or vaccination cohorts by fitting a
model of exponential decay. A similar decay in neutralization
titers was found induced by vaccination, and from a natural
infection by SARS-CoV-2. Therefore, they estimated the
half-life of decay in neutralization titers using a study on con-
valescent subjects, and their data of up to 8 months after
infection. They found an estimated half-life of 1,08 days of
neutralizing antibodies after vaccination, which was then
used to model a 250-day protection, and decay in neutraliza-
tion after vaccination. Their model predicted that a high initial
starting efficacy of 90% of a vaccine would drop to 70% by
250 days, while a starting efficacy of 70% would drop to
33% after 250 days.10 These findings suggest that immune
responses might wane over time. Their model also gave a
prediction of the long-term efficacy of the vaccines. Since
they demonstrated their model by suggesting that a natural
antibody response is similar to the one induced by vaccina-
tion, it can be supported by the fact that the BNT162b2 vac-
cine was shown to have a lower efficacy against the B.1.351
variants of SARS-CoV-2. Much lower titers of neutralizing
antibodies were developed in only 60% and 70% of people
after week 1 and week 3 of the second dose of the vaccine,
respectively, suggesting a loss of potency of the vaccine-
induced neutralizing titers because of the E484K mutation in
the variant.11 Furthermore, the neutralization level needed to
prevent severe disease is fortunately six times lower than
that needed to have protection from any symptomatic
disease,10 meaning that vaccination would still provide pro-
tection against severe disease even at much lower antibody
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levels. A booster might still become necessary after 8–12
months, as suggested by the Pfizer.11 Randomized control
trials can also overestimate the protection provided by
vaccines compared with the real-world where logistical
problems exist, such as nonoptimal temperature storage of
vaccines, and delays in administering the second dose.12
It would not be economically feasible to vaccinate entire
populations at one time for every couple of months. More
so, it is clear that humans cannot go with social distancing,
and other preventive measures for a long period of time
either. Hence, the only strategy to manage this ongoing pan-
demic is to develop a COVID-19 vaccine that can provide
long-term clinical benefits along with socioeconomic bene-
fits. A successful COVID-19 vaccine should pass clinical
safety, efficacy, large-scale distribution, and production.13
Around 15 vaccines are still under trial while many are
already under distribution with some participants completing
the course of immunization. With many vaccines available,
and others still on the rise, there is much dispute about their
true efficacy and reliability.
Although great effort is rendered into developing and
deploying vaccines, the vaccine coverage rate among the
population is also an important factor that decides success-
ful immunization.14 Generally, vaccine development would
take years with thorough trials for safety measurements
before global distribution. Hence, the public acceptance for
a multitude of COVID-19 vaccines that were developed
within a short period of time remains skeptical. Therefore,
vaccine hesitancy is a major hindrance when distributing to
certain regions especially the uneducated areas. It has been
classified as a major threat to global health by WHO as it dis-
rupts the process of eventually eradicating the disease in
question. An approximation of 67% herd immunity may be
possible only if vaccination programs are made mandatory
coupled with education programs to eliminate the factor of
vaccine hesitancy.15 However, the recent rise in vaccine
hesitancy because of concerns about its safety has led to a
slower rise in immunity, and a faster outbreak in many dis-
eases such as measles and polio.16 Thus, this conflict
affects not only the individual who is hesitant to take the vac-
cine, but the whole community, making it impossible to
reach the goal of successful herd immunization. The overall
morbidity and mortality rate of COVID-19 has been high
because of rapid virus transmission, and therefore several
countries had initiated early research and development for a
vaccine. Understanding the specific challenges in carrying
out the vaccination across the world will vary from region to
region as some may suffer from financial burdens, and
others with belief barriers. However, facilitators for vaccine
acceptance would help a great deal in improving vaccine
coverage rate and are even more vital in a time-dependent
pandemic.17
Developing countries suffer the most because of inade-
quate education, and lack of awareness toward public health
issues.18 The inability to finance vaccination facilities, and
vaccine hesitancy makes for a larger struggle to herd immu-
nity.19 Pakistan, in particular, has suffered from the failures
of previous vaccination programs as a result of fabrications
that fed to vaccine hesitancy.20 For example, polio is still not
eradicated from Pakistan as a result of the misconception of
its supposed false side effects because of which the disease
now poses a threat to many vulnerable and unprivileged
children.21 These fabrications turn to stubborn beliefs, and
become barriers toward achieving herd immunity among the
nation. Furthermore, a combination of other key factors such
as severity of the disease, previous vaccination history, lack
of belief in healthcare services, route of administration of
vaccine, economic and educational status of the individuals,
recommendations from doctors, and cost of vaccine also
determines the acceptance of vaccines.22 In this study, we
analyze the acceptance rates of COVID-19 vaccine, beliefs,
and barriers that might prevent the participants from being
vaccinated against the COVID-19 among the general popu-
lation in Pakistan. With the previous polio vaccination failure
because of the very factor of perceptive barriers, this study
aims to prevent the repeat of such drastic public health
catastrophes.
MATERIALS AND METHODS
The cross-sectional study was conducted among the gen-
eral public of Pakistan between January 28, 2021 and
February 11, 2021. All individuals aged $ 18 years of either
gender, that is, male or female residing in the four provinces
of Pakistan i.e., Sindh, Punjab, Balochistan, and Khyber Pak-
htunkhwa were included in the survey. All those who refused
to provide with an informed consent were excluded. A com-
prehensive validated self-administered questionnaire was
distributed through social media platforms such as What-
sApp, Facebook, and e-mails to the participants. The ques-
tionnaire was administered in the native language of the
population, that is, Urdu language.
The questionnaire composed of an introductory paragraph
stating the primary aim and the objectives of the study,
description on voluntary participation, followed by a manda-
tory informed consent obtained from all participants. The
participants were also informed that they could leave the
survey at free will and at any time they feel uncomfortable
before its completion.
The participants were assured that their anonymity and
confidentiality would be maintained as all data provided by
the participants would be kept confidential. The outline of
the questionnaire was adapted from the previous study con-
ducted by Magadmi and Kamel (2020) with some modifica-
tions according to locality.23 The questionnaire was
reviewed by two senior professors for validity and reliability.
The questionnaire was modified based on their recommen-
dations and suggestions. We further carried out a pilot sur-
vey on 15 study participants that yielded the questionnaire
to be concise, easily understandable, and requiring 3–5
minutes to complete. The questionnaire consisted of five
major sections that collected data on sociodemographic
parameters, beliefs toward COVID-19 vaccination, COVID-
19 vaccine acceptance, potential barriers that may prevent
from being vaccinated, and factors that can improve COVID-
19 vaccine acceptance. An additional question was created
to inquire about the administration of polio vaccine among
the individual’s children to compare the beliefs regarding the
polio vaccine versus that of the COVID-19 vaccine.
The data was analyzed using the Statistical Package for
Social Sciences (SPSS) software package (version 16) (IBM
Corporation, Armonk, NY). All categorical variables were
reported using frequencies and percentages while mean and




Univariate logistic regression was applied to access the
association of sociodemographic variables, beliefs, barriers,
and factors that may improve COVID-19 vaccination with its
acceptance rate among the population. A P value of # 0.05
was considered as statistically significant.
RESULTS
Sociodemographic factors of the participants. A total
of 1,900 questionnaires were distributed to account for
incomplete responses out of which 1,778 were completely
filled, giving a response rate of 93.6%. The mean age of the
participants was 23.29 6 3.61 years. 625 (35%) were males,
807 (45%) were university graduates, while a minor propor-
tion 156 (9%) was married. Most 473 (27%) earned between
51,000 rupees and 100,000 rupees. The highest proportion
of the respondents belonged to Punjab 818 (46%) followed
by Sindh 493 (28%). Only 85 (5%) of participants suffered
from comorbidities. More than half 979 (55%) self-reported
their overall health as good/satisfactory. Upon asking the
probability of being infected with COVID-19, majority 824
(46%) stated they do not think they would get the infection in
future, while 305 (17%) stated they have been already
infected with the virus. The participants were also
asked whether they believe in getting their children vacci-
nated against polio virus to which 419 (24%) showed disap-
proval (Table 1).
Acceptance and beliefs toward COVID-19 vaccination.
The beliefs of the participants regarding the COVID-19 vac-
cine (Figure 1) was accessed with three leading questions
pertaining to the effectiveness, safety profile, and efficacy in
preventing complications of the disease. About 782 (44%) of
respondents believed the vaccine to be safe, 885 (50%)
were not sure about it, and 111 (6%) considered it to be
unsafe. Regarding the effectiveness, 783 (44%) considered
it to be effective against the virus, 903 (51%) were unsure,
and the remaining 92 (5%) believed the vaccine was ineffec-
tive. When asked whether the respondents believe the best
way to avoid COVID-19 complications is by administering
the vaccine, the highest proportion 946 (53%) answered in
affirmative, 394 (22%) did not believe it, and 438 (25%) were
not sure. Overall, 1,280 (72%) of participants planned to
receive the COVID-19 vaccine, whereas 498 (28%) refused
to get vaccinated. About 981 (55%) stated they would
receive the vaccine as soon as it is available, whereas 797
(44%) would not. Upon asking their preference for different
COVID-19 vaccines, 863 (49%) prioritized internationally
made imported vaccines, 171 (9%) preferred locally made
vaccines, while the type of vaccine did not matter to 744
(42%) of respondents (Figure 2).
Barriers and potential recommendations that may
improve COVID-19 vaccination. Regarding the barriers
associated with COVID-19 vaccine acceptance (Figure 3),
738 (42%) were concerned about the vaccine’s side effects,
436 (25%) believed that the vaccine will not help against the
virus, and only 79 (4%) labeled the vaccine as a conspiracy.
Furthermore, 233 (13%) stated they do not need the vaccine
because they follow all preventive measures seriously. The
participants were asked for suggestions that might improve
vaccination rates to which 785 (44%) agreed to receive it
upon a physician recommendation, 568 (32%) required fur-
ther validation from research studies to prove the efficacy
and safety of the vaccine, 103 (6%) would receive the vac-
cine if made mandatory by the government, 62 (4%) would
receive it if made mandatory by their affiliated organization/
company, and 152 (9%) would get vaccinated upon the rec-
ommendation of their family/friends (Figure 4).
Factors associated with the acceptance of COVID-19
vaccination. On univariate regression models, male gender
(odds ratio [OR]: 1.284 [95% CI: 1.029–1.602], P 5 0.027),
postgraduates (OR: 2.151 [95% CI: 1.181–3.917], P 5
0.012), graduates (OR: 2.017 [95% CI: 1.312–3.100], P 5
0.001), healthcare workers (OR: 2.398 [95%: 1.163–4.942], P
5 0.018), residence of Sindh (OR: 2.128 [95% CI:
1.571–2.881], P , 0.001), residence of Punjab (OR: 1.621
[1.243–2.113], P , 0.001), and residence of Balochistan
(OR: 1.661 [1.049–2.630], P5 0.030) were significantly asso-
ciated with COVID-19 vaccination. Those who believed in
the efficacy of polio vaccination (OR: 1.496 [95% CI:
1.055–2.121], P 5 0.024), believed that the vaccine is safe
(OR: 7.696 [95% CI: 5.735–10.327], P , 0.001), believed
that vaccine is effective (OR: 3.565 [95% CI: 2.793–4.552], P
, 0.001), believed vaccine is the only way to avoid COVID-
19 complications (OR: 6.269 [95% CI: 4.693–8.373], P ,
0.001), and preferred internationally made/imported vac-
cines (OR: 1.483 [95% CI: 1.189–1.850], P , 0.001) showed
positive acceptance rates.
Lastly, factors including recommendation by a physician
(OR: 10.847 [95% CI: 6.471–18.180], P , 0.001), further
studies proving safety and efficacy of the vaccine (OR: 5.342
[95% CI: 3.191–8.944], P , 0.001), if made compulsory by
government (OR: 6.638 [95% CI: 3.465–12.719], P , 0.001),
if declared mandatory by affiliated institute/company (OR:
4.202 [95% CI: 2.072–8.522], P , 0.001), recommendation
by a family member and/or friends (OR: 4.629 [95% CI:
2.517–8.334], P , 0.001), and way of administering other
than injection (OR: 3.830 [95% CI: 1.558–9.418), P 5 0.003)
were significantly associated with vaccine acceptance
(Table 2).
DISCUSSION
In the 21st century, one of the most groundbreaking inter-
ventions in the healthcare system is the introduction of vac-
cination. This health security measure is facing numerous
challenges worldwide, despite the known benefits of vacci-
nation. The adoption of vaccination among the population is
influenced by several variables, such as geography, time,
social status, human behavior, and ethnicity.24–26 Public per-
ception of the benefits and relative risks of vaccination have
been reported to be a significant barrier to vaccine accep-
tance.27 Although a number of studies regarding COVID-19
vaccine acceptance are being undertaken worldwide, the
number still remains limited at present. Our results show that
vaccine acceptance was 72% in this study, which is in
accordance with the results obtained from the US-based
study that reported vaccine acceptance of the general popu-
lation to be 80% while another study based in China
reported vaccine acceptance to be 72.5% of the general
population.28,29 Our study shows that the vaccine accep-
tance (72%) among participants was higher compared with
some other studies, such as those conducted in South Africa
(64%), Russia (54%), France (59%), Poland (56%), and Hun-
gary (56%).30
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Regarding willingness, the results showed that majority
(55%) of the study population were willing to take the
COVID-19 vaccine as soon as it is available, and this trend
was noted to be similar to several other countries. Our study
shows that 28% of the study population are reluctant in get-
ting vaccinated upon its availability. IPSOS survey reported
disapproval of the COVID-19 vaccine in 47% Russians, 41%
French, 33% Italian, 30% Turkish, 33% Americans, 24%
Canadians, and 15% English (Great Britain), 13% Indian,
and 3% Chinese, once available.31 A survey conducted in
Malaysia (a nation in Southeast Asia), with recorded
COVID-19 cases of just over 4,000 and less than 100 deaths
during the research period in April 2020, showed a higher
(94.3%) intention to vaccinate, of which 48.2% stated a defi-
nite intention.32
The greatest obstacle that stands against the COVID-19
vaccine acceptance among the participants is the concerns
regarding the adverse effects and efficacy of the vaccine,
TABLE 1
General characteristics of the participants




































































What is your best guess as to whether you will get the coronavirus within the next 6 months?
I think I will get a severe case of COVID-19
I think I will get a mild case of COVID-19
I don’t think I will get the coronavirus infection















along with the lack of knowledge and belief in vaccines. This
finding is consistent with studies of other vaccines.33 A poll
conducted in the United States showed that if assurance
regarding the safety of the COVID-19 vaccine was given,
approximately 75% of the population would agree to get the
vaccine.34 Some participants also believed that strict pre-
cautionary measures (regular handwashing and the usage of
gloves and masks) were enough to replace the need to get
the vaccine entirely.
Based on the overall response, the following options
would encourage future COVID-19 vaccinations and accep-
tance, that is, if more physicians started to recommend the
vaccines to their patients, and if more vaccine-related stud-
ies showed safety and effectiveness. Additionally, informa-
tion regarding vaccine safety should be disseminated in a
straightforward manner, so that it can be interpreted by indi-
viduals at all levels of education to improve vaccine accep-
tance by the public. Moreover, there is evidence that people
whose physicians recommend vaccines are more likely to
get vaccinated compared with ones who are not
recommended.35 It has been argued that physicians are
more suited and qualified to address concerns, side effects,
and misinformation regarding the vaccine, and to also
convey the magnitude of COVID-19 infection in a tailored
manner for each patient.36 However, owing to the time con-
straints at primary healthcare encounters, and the potential
need for staff training to address vaccine-related concerns,
healthcare providers should explore an alternative approach
in which vaccine counselors use motivational interviewing to
approach vaccine-hesitant individuals. This approach has
been successful at increasing rates of infant vaccine cover-
age and adolescent human papillomavirus vaccination.37
This cross-sectional survey was conducted using a vali-
dated, self-administered electronic questionnaire that was
distributed to the general public of Pakistan via different
online platforms, and therefore has certain limitations. Firstly,
the lack of Internet availability and access to social media
platforms may have had an impact on the survey population
due to which a bias in reporting results should be consid-
ered. Secondly, the difference in public perceptions that
may be associated with sociodemographic factors were not
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DO YOU THINK THAT THE BEST WAY TO AVOID THE




FIGURE 1. Pie diagrams showing the response of the participants
regarding their beliefs (safety and effectiveness) towards COVID-19
vaccination. This figure appears in color at www.ajtmh.org.
72%
28%













WILL YOU RECEIVE VACCINATION AS SOON AS POSSIBLE
WHEN THE COVID-19 VACCINE IS AVAILABLE? 
Yes No
FIGURE 2. Pie diagrams showing the response of the participants
regarding the acceptance of COVID-19 vaccination. This figure
appears in color at www.ajtmh.org.
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FIGURE 3. Response of the participants regarding the barriers associated with COVID-19 vaccination. This figure appears in color at www.
ajtmh.org.
FIGURE 4. Response of the participants regarding the factors that can encourage public to get COVID-19 vaccination. This figure appears in
color at www.ajtmh.org.
TABLE 2
Factors affecting COVID-19 vaccine acceptance among the participants
Study variables















































































































































































What is your best guess
as to whether you will
get the coronavirus
within the next 6
months?
I think I will get a
severe case of COVID-19
I think I will get a mild
case of COVID-19
I don’t think I will get
the coronavirus infection


















Do you believe in getting
your children vaccinated
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19 vaccination, whenever
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best way to avoid the
complications of COVID-
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large enough to represent the entire Pakistani population, so
the results should be carefully generalized.
Nevertheless, the major findings of this study can be used
in planning potential vaccination campaigns. The study iden-
tifies concerns among the participants regarding the safety
and efficacy of COVID-19 vaccines, and hence provides a
valuable important perspective for possible interventional
educational programs to enhance vaccination rates. This
study also serves an important baseline to conduct further
studies in a larger population to obtain an insight on the
behavior, and public perception of upcoming COVID-19 vac-
cines. Lastly to the best our knowledge, this is the first study
conducted to determine the COVID-19 vaccine acceptance
rates on a large population of 1,778 citizens, and represents
participants from all four provinces of Pakistan.
CONCLUSION
Reasons for vaccine hesitancy should further be evaluated
by the government to ensure more acceptance of the
COVID-19 vaccine by the public. Herd immunity can only be
achieved if the beliefs regarding vaccine safety and con-
cerns are addressed. Positive and accurate information
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I am concerned about
the vaccine’s side effects
I don’t believe that the




I don’t need the
vaccine because I follow
preventive measures
seriously, wash my
hands, wear a mask and
gloves







































recommended it to me
If more studies showed
that the vaccine is safe
and effective
If it was made
compulsory by
Government of Pakistan
If it was made
mandatory by company/
institute where I work
If my family or friends
get vaccinated
If there is a way other
than injection


































through physicians, and the social media, to the general
public.
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